arrow
T

Thierry Petit

icans
H指数:37
被引数:5,586

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort.

HER2阴性低表达雌激素和孕激素受体转移性乳腺癌患者的特征和结局:多中心ESME队列研究

2026-05-180
OAAI
18F-Fluorodeoxyglucose PET-CT evaluation after one course of neoadjuvant therapy fails to predict pCR in HER2 + BC patients: a prospective and multicentric French study

18F-Fluorodeoxyglucose PET-CT评估在完成一周期新辅助治疗后无法预测HER2+BC患者的pCR:一项前瞻性、多中心法国研究

2025-12-030
OAAI
Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMMUNE-03

纳武利尤单抗联合伊匹木单抗与卡培他滨作为新辅助化疗后仍有残留病灶的三阴性乳腺癌患者的术后治疗:一项多中心、随机、开放标签的II期试验——BREASTIMMUNE-03

2025-11-210
OAAI
Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database

无铂间期(PFI)及维持治疗在复发性卵巢癌中的作用:解释生存率的法国真实世界ESME卵巢数据库分析

2025-08-070
PRE
Advanced High-Grade Serous Ovarian Cancer Treated With Intensive Cytoreductive Surgery And Chemotherapy: Prognostic Impact Of Lymph Node Involvement: Analysis Of The French National ESME-Unicancer Database

高级别浆液性卵巢癌经强化细胞减灭术和化疗治疗:淋巴结受累的预后影响:法国国家ESME-Unicancer数据库分析

2025-02-010
PRE
Long-term behavioral symptom clusters among survivors of early-stage breast cancer: Development and validation of a predictive model
2024-09-090
PRE
Trajectories and predictors of peripheral neuropathy after neoadjuvant chemotherapy in a prospective cohort of 11,014 patients with early breast cancer
2024-05-020
PRE
Pathological complete response with chemotherapy and immune checkpoint inhibition in triple negative inflammatory breast cancer (TN-IBC)
2024-05-020
PRE
Prognosis and clinicopathological characteristics of HER2-negative metastatic breast cancers with low expression of hormone receptors: real world evidence from the French ESME cohort
2024-05-020
PRE
First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort
2024-01-014
PRE
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer
2023-12-190
OAAI
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials
2023-03-290
PRE
Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database
2023-03-084
OAAI
Baseline quality of life and chemotherapy toxicities in patients with early breast cancer

早期乳腺癌患者的基线生活质量和化疗毒性

CANCER
IF5.1
2023-01-152
PRE
Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study
BREAST
IF7.9
2022-10-016
OAAI